{
    "id": 32768,
    "fullName": "MET Y1003S",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MET Y1003F lies within the juxtamembrane domain of the Met protein (PMID: 30885356). Y1003S has been identified in the scientific literature (PMID: 30885356), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 18129,
                    "pubMedId": 30885356,
                    "title": "MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30885356"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4233,
        "geneSymbol": "MET",
        "terms": [
            "MET",
            "AUTS9",
            "c-Met",
            "DFNB97",
            "HGFR",
            "RCCP2"
        ]
    },
    "variant": "Y1003S",
    "createDate": "03/12/2020",
    "updateDate": "03/12/2020",
    "referenceTranscriptCoordinates": {
        "id": 188410,
        "transcript": "NM_000245",
        "gDna": "chr7:g.116771969A>C",
        "cDna": "c.3008A>C",
        "protein": "p.Y1003S",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20924,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring MET Y1003S demonstrated a response to Xalkori (crizotinib) that lasted more than 10 months, with  improvement in lung and lymph node lesions (PMID: 30885356).",
            "molecularProfile": {
                "id": 35407,
                "profileName": "MET Y1003S"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18129,
                    "pubMedId": 30885356,
                    "title": "MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30885356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35407,
            "profileName": "MET Y1003S",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 188410,
            "transcript": "NM_000245",
            "gDna": "chr7:g.116771969A>C",
            "cDna": "c.3008A>C",
            "protein": "p.Y1003S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}